gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Paraoxonase 1

paraoxonase, PON1, paraoxonase 1, PON, ESA
The enzyme encoded by this gene is an arylesterase that mainly hydrolyzes paroxon to produce p-nitrophenol. Paroxon is an organophosphorus anticholinesterase compound that is produced in vivo by oxidation of the insecticide parathion. Polymorphisms in this gene are a risk factor in coronary artery disease. The gene is found in a cluster of three related paraoxonase genes at 7q21.3. [provided by RefSeq, Oct 2008] (from NCBI)
Top mentioned proteins: HDL, AGE, HAD, CAN, ACID
Papers using paraoxonase antibodies
Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids.
Parkinson John, In PLoS ONE, 1995
... Sequences for PON1 mutants were incorporated into expression plasmids by GenScript (Piscataway, NJ, USA) ...
Papers on paraoxonase
Increased HDL Size and Enhanced Apo A-I Catabolic Rates Are Associated With Doxorubicin-Induced Proteinuria in New Zealand White Rabbits.
Pérez-Méndez et al., Mexico. In Lipids, Feb 2016
Apo E increased and apo A-I decreased in HDL, whereas PON-1 activity increased in proteinuric rabbits.
Impact of plant-based diet on lipid risk factors for atherosclerosis.
Jankowski et al., Gdańsk, Poland. In Cardiol J, Feb 2016
The activity of paraoxonase-1 and 8-iso-prostaglandin F2α concentration were also not different between the study groups.
Paraoxnase1 Gene Polymorphism in Childhood Idiopathic Nephrotic Syndrome.
Haider et al., Kuwait, Kuwait. In Nephron, Feb 2016
BACKGROUND: Paraoxonase1 (PON1) is a serum enzyme bound to high-density lipoproteins with antioxidant properties.
HDL-A molecule with a multi-faceted role in coronary artery disease.
Saini et al., New Delhi, India. In Clin Chim Acta, Feb 2016
CONCLUSION: The changes in HDL composition (primarily in protein components-apolipoproteins, paraoxonase etc.) can occur under pathological conditions and can affect the functionality of HDL.
The effect of the paraoxonase 1 (PON1) T(-107)C polymorphism on serum PON1 activity in women is dependent on fatty acid intake.
Schneider et al., Pelotas, Brazil. In Nutr Res, Jan 2016
Paraoxonase 1 (PON1) is an enzyme that prevents the peroxidation of lipoprotein and cell membranes.
Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies.
Dullaart et al., Groningen, Netherlands. In Atherosclerosis, Jan 2016
BACKGROUND: Paraoxonase-1 (PON-1) has been suggested to be associated with cardiovascular disease (CVD) risk, however, aspects of the association, such as shape and independence from conventional risk factors are still uncertain.
Chemical Characterization, Free Radical Scavenging, and Cellular Antioxidant and Anti-Inflammatory Properties of a Stilbenoid-Rich Root Extract of Vitis vinifera.
Rimbach et al., Kiel, Germany. In Oxid Med Cell Longev, Dec 2015
Furthermore, the root extract could induce the antiatherogenic hepatic enzyme paraoxonase 1 and downregulate proinflammatory gene expression (interleukin 1β, inducible nitric oxide synthase) in macrophages.
Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials.
Sahebkar et al., Italy. In Prog Lipid Res, Oct 2015
BACKGROUND: Decreased activity of the enzyme paraoxonase-1 (PON1) has been demonstrated in cardiovascular diseases.
Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies.
Amoli et al., Tehrān, Iran. In J Diabetes Res, 2014
We found significant association between CTLA-4, IL-18, VDR, TAP2, IL-12, and CD4 genes and T1DM, HNFα and MODY, haptoglobin, paraoxonase, leptin, TCF7L2, calreticulin, ERα, PPAR-γ2, CXCL5, calpain-10, IRS-1 and 2, GSTM1, KCNJ11, eNOS, VDR, INSR, ACE, apoA-I, apo E, adiponectin, PTPN1, CETP, AT1R, resistin, MMP-3, BChE K, AT2R, SUMO4, IL-10, VEGF, MTHFR, and GSTM1 with T2DM or its complications.
Antioxidant properties of HDL.
Durrington et al., Manchester, United Kingdom. In Front Pharmacol, 2014
A number of candidates have been suggested to be responsible for HDL's antioxidant function, with paraoxonase-1 (PON1) perhaps the most prominent.
Two- and three-locus haplotypes of the paraoxonase (PON1) gene are associated with coronary artery disease in Asian Indians.
Das et al., New Delhi, India. In Gene, 2012
only one SNP at a single locus but several haplotype combinations of PON1 coding and promoter-region polymorphisms were associated with the risk of or protection against coronary artery disease
Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer's disease: a meta-analysis.
Li et al., Chongqing, China. In Neurosci Lett, 2012
PON1 gene polymorphisms (Q192R, L55M) were unlikely to contribute to Alzheimer disease susceptibility.
Application of the buccal micronucleus cytome assay and analysis of PON1Gln192Arg and CYP2A6*9(-48T>G) polymorphisms in tobacco farmers.
Kvitko et al., Porto Alegre, Brazil. In Environ Mol Mutagen, 2012
PON1 Gln192Arg and CYP2A6*9(-48T>G) polymorphisms were associated with DNA damage induced by pesticides and cell death in Brazilian tobacco farmers.
Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen, and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma.
Uemura et al., Hirakata, Japan. In Med Mol Morphol, 2012
Results suggest that immunohistochemical analysis of CD82 (KAI1) and epithelial-specific antigen (ESA, EPCAM) to distinguish chromophobe renal cell carcinoma (ChRCC) from renal oncocytoma (RO).
Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study.
Mackness et al., Tarragona, Spain. In Dis Markers, 2011
No association between coronary artery calcification and PON1 was found.
Paraoxonase-1 is a major determinant of clopidogrel efficacy.
Taubert et al., Nieuwegein, Netherlands. In Nat Med, 2011
PON1 as a key factor for the bioactivation and clinical activity of clopidogrel and its efficacy after stent implantation.
Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome.
Deanfield et al., London, United Kingdom. In Jama, 2009
OBJECTIVES: To compare vascular structure and function in patients with positive antiphospholipid antibodies (aPL) with controls and to assess their relationship with paraoxonase activity.
Directed enzyme evolution via small and effective neutral drift libraries.
Tawfik et al., Israel. In Nat Methods, 2008
We describe methods for preparing such libraries, using serum paraoxonase (PON1).
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.
Hazen et al., Cleveland, United States. In Jama, 2008
This study provides direct evidence for a mechanistic link between genetic determinants and activity of PON1 with systemic oxidative stress and prospective cardiovascular risk, indicating a potential mechanism for the atheroprotective function of PON1.
Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon.
Lu et al., Singapore, Singapore. In Nature, 2007
Polo directly phosphorylates Partner of Numb (Pon, ref. 16), an adaptor protein for Numb, and this phosphorylation event is important for Pon to localize Numb.
share on facebooktweetadd +1mail to friends